Facebook Tracking Image

National Comprehensive Cancer Network

Educational Events & Programs


NCCN POLICY SUMMIT UPDATES  >  Click here for the article


On December 10, 2018, NCCN hosted a summit entitled, Patient Advocacy Summit: Advocating for Equity in Cancer Care. The summit provided an opportunity for a varied group of stakeholders including patients, patient advocacy organizations, industry, providers, and payers to thoughtfully discuss equitable patient access to high-quality oncology care and present best practices regarding how patient advocacy organizations can influence health care policy moving forward.

Prior to the summit, NCCN conducted an environmental scan that consisted of stakeholder meetings with patient advocates. The meetings examined current disparities in access, cost, and treatment in oncology, and identified policy strategies to address these significant barriers for patients with cancer.

An article was published in the Journal of the National Comprehensive Cancer Network―JNCCN.

Please check back often for additional updates regarding the summit. If you have any meeting content or agenda questions, please contact James McCanney, JD, Policy/Advocacy Fellow. For any media questions, please contact Rachel Darwin, Public Relations Manager.

Supported by Adaptive Biotechnologies; AmerisourceBergen; an educational donation provided by Amgen; Apobiologix, a division of ApoPharma USA, Inc; Astellas; AstraZeneca through its NCCN Corporate Council Membership; Celgene Corporation; Eisai, Inc; EMD Serono; a non-restricted medical education grant from Gilead Sciences, Inc; a grant from Genentech, a Member of the Roche Group; HELSINN; Heron; Incyte Corporation; Janssen Pharmaceutical Companies of Johnson & Johnson; Juno Therapeutics; Kite, a Gilead Company; an independent educational grant from Merck & Co., Inc; Regeneron; Servier; an unrestricted sponsorship from TESARO; Verastem. Sponsored by Bristol-Myers-Squibb; Boehringer Ingelheim Pharmaceuticals, Inc; Clovis Oncology, Inc; Dendreon; Novartis Pharmaceuticals Corporation; Sandoz, A Novartis Division. The National Comprehensive Cancer Network’s 2018 Patient Advocacy Summit was funded in part by a sponsorship from Jazz Pharmaceuticals, Inc; This activity is supported by a contribution from Lilly; This activity was made possible by Pharmacyclics, an AbbVie Company and Janssen Biotech, Inc.

Access the Library of White Papers!

NCCN offers a broad library of white papers from previous summits that may be pertinent to your organization.

View Supporter Opportunities.

NCCN offers organizations various supporter opportunities.